Navigation Links
UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam
Date:12/3/2007

t fully controlled despite treatment with one or two other antiepileptic drugs. The third study is a randomized, double-blind, placebo-controlled trial with flexible dosing designed to evaluate the safety and tolerability of brivaracetam in patients with uncontrolled partial onset or primary generalized seizures. First results of these studies are expected in mid 2009.

About Brivaracetam: Brivaracetam has distinct pharmacological differences as well as having some structural similarity to the AED Keppra(R) (levetiracetam). In preclinical studies brivaracetam was shown to have a 10- fold higher affinity for synaptic vesicle protein 2A (SV2A) than Keppra(R). Brivaracetam also has inhibitory activity at neuronal voltage-dependent sodium channels whose abnormal function is understood to contribute to electrical discharges associated with seizures. These differences may explain brivaracetam's antiepileptic activity, clinical efficacy and tolerability.

About Epilepsy: Epilepsy is a chronic neurological disorder affecting more than 2.5 million Americans regardless of race, age or sex. Between 70-80% of individuals are successfully treated with one of the more than 20 antiepileptic drugs now available. However, 20-30% of patients have either intractable or uncontrolled seizures or have significant adverse side effects secondary to medication, highlighting the ongoing need for the development of new antiepileptic drugs.

About Keppra(R) in the U.S.: Keppra(R) tablets and oral solution are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy, myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. Keppra(R) injection is indicated as adjunctive therapy in the treatment of myoclonic seizures in JME
'/>"/>

SOURCE UCB, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... out to benefit Core Compassion Project. Core Compassion Project is a non-profit ... program to reduce the side effects of cancer treatments and recover their mobility, ...
(Date:9/4/2015)... ... September 04, 2015 , ... Mike Day, a former Navy SEAL who was ... Ironman World Championships in Kona on October 10th. , Mike is running the race ... through combat and the cutting-edge treatments that restore their quality of life. ...
(Date:9/4/2015)... ... 04, 2015 , ... Having access to a doctor can sometimes be a ... of unnecessary emergency room visits which affects hospitals’ abilities to provide quality service to ... a solution to alleviate this problem has recently presented itself, the new telemedicine platform ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... are prophetic details involving the Pope’s upcoming trip to the United States. , Yisrayl lays ... his role with the Vatican and society is. Yisrayl also provides the meaning of his ...
(Date:9/3/2015)... Angeles, CA (PRWEB) , ... September 03, 2015 , ... ... patients as to the best practices when preparing for a bariatric procedure, some patients ... a procedure. Apart from the basic instructions typical for many types of surgery that ...
Breaking Medicine News(10 mins):Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2Health News:Dr. Feiz and Associates Answer August's ‘Patient Submitted Question of the Month’: “How Can I Prepare for Weight Loss Surgery” 2
... UC Irvine neuroscientists have received $2 million to ... findings could lead to clinical research and treatment of ... UCI scientists hope to gain a greater understanding of ... the auditory cortex. , "We still don,t know how ...
... a new imprint devoted to the relationships between men and ... HOME. AFRAID TO GO HOME, a 420 page paperback, is ... advantage of at work by the Good Ol, Boys, and ... herself and her children from at home."One of the reasons ...
... to Consumer Reports Health News for health and ... issues pertaining to the efficacy and safety of ... health, diet and nutrition, food safety, and fitness. ... the effectiveness and affordability of prescription drugs, and ...
... Abnormal Heart RhythmsAUSTIN, Texas, March 3 On ... Institute at St. David,s Medical Center became the ... long-awaited NaviStar(R) RMT ThermoCool(R) Catheter to treat abnormal ... received FDA approval on Friday, Feb. 27, 2009.The ...
... effectiveness of the only tuberculosis vaccine approved for humans ... pre-clinical test, report scientists at The University of Texas ... ,s Advance Online Publication March 1. Their findings resulted ... the National Institutes of Health (NIH). , Bacille ...
... to zero, saves nearly $2 millionCARY, Ill., March 3 ... or immobilized are at a higher risk for the ... conditions that can significantly reduce quality of life. Establishment ... of heel protectors resulted in 100 percent prevention of ...
Cached Medicine News:Health News:AFRAID TO GO HOME, A Novel About Violence Against Women, Released By Tristan/Isolde Publishing 2Health News:Consumer Reports Health News 2Health News:Consumer Reports Health News 3Health News:Texas Cardiac Arrhythmia Institute at St. David's Medical Center First in Nation to Use NaviStar(R) RMT ThermoCool(R) Catheter Since Technology Received FDA Approval 2Health News:Texas Cardiac Arrhythmia Institute at St. David's Medical Center First in Nation to Use NaviStar(R) RMT ThermoCool(R) Catheter Since Technology Received FDA Approval 3Health News:TB breakthrough could lead to stronger vaccine 2Health News:TB breakthrough could lead to stronger vaccine 3Health News:Clinical Intervention Eliminates Heel Ulcer Incidents in ICU 2
(Date:9/4/2015)... Sept. 4, 2015  Pharmaceutical companies today rely ... Field-Based Medical Specialists (FBMS) to build and strengthen ... thought leaders in critical therapeutic areas. ... teams, companies are expanding the critical MSL function ... with corporate objectives and to achieve regional consistency, ...
(Date:9/4/2015)... Texas , Sept. 4, 2015  Luminex Corporation ... present at the Morgan Stanley Global Healthcare Conference to ... Grand Hyatt Hotel in New York City ... at 11:40 a.m. Eastern time on Friday, September 18, ... accessed at Luminex Corporation,s website at http://www.luminexcorp.com . ...
(Date:9/4/2015)... SOUTH PLAINFIELD, N.J. , Sept. 4, 2015 ... is pleased to announce five recipients of its ... to Realize Innovation, Vision and Empowerment), designed to ... the Duchenne muscular dystrophy (DMD) community. The announcement ... for the international World Duchenne Awareness Day on ...
Breaking Medicine Technology:New Study Presents Tactics and Insights on How to Effectively Globalize Medical Science Liaison Programs in the Pharmaceutical Industry 2Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4
... March 14, 2012  MAKScientific, LLC, a privately held company ... pathways, today announced that it has entered into an ... (NASDAQ: BIIB ) to develop and commercialize ... and other neurodegenerative diseases. Under the agreement, ...
... March 14, 2012  Apricus Biosciences, Inc. Chief Executive Officer, ... http://www.apricusbio.com ) said in an interview with Charles Sample ... from a clinical development company to an income-generating, hybrid ... at: http://www.ceonews.tv/apri Damaj cited the ...
Cached Medicine Technology:Apricus Biosciences, Inc. (APRI) Transforms From Development Company to Income Generating! 2Apricus Biosciences, Inc. (APRI) Transforms From Development Company to Income Generating! 3Apricus Biosciences, Inc. (APRI) Transforms From Development Company to Income Generating! 4
... Blind Performance Specimens are intended for ... handling and transportation guidelines, including chain ... Testing Programs regulated by the Substance ... (SAMHSA), Health and Human Services Department ...
... Reticulocyte Stain is an aqueous ... use in manual methods of ... has a one year shelf ... and can be used in ...
Seroconversion and Antigen Panel Chart...
... Amplichek CT/GC Controls are ... the precision of test procedures ... Neisseria gonorrhoeae. Since they are ... used with either urine or ...
Medicine Products: